1-acetoxy-2-(1H-imidazol-1-yl)butane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-acetoxy-2-(1H-imidazol-1-yl)butane
• 英文别名: 2-Imidazol-1-ylbutyl acetate
• 化学式: C₉H₁₄N₂O₂
• 分子量: 182.222
• InChiKey: JNMORQACKRWTKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-acetoxy-2-(1H-imidazol-1-yl)butane 在 盐酸 作用下， 以 乙醇 为溶剂， 以16%的产率得到1-(1H-imidazol-1-yl)butan-2-ol hydrochloride
  参考文献：
  名称：

  Anti-Plasmodium activity of imidazole–dioxolane compounds

  摘要：

  A series of imidazole-dioxolane compounds, which we hypothesize should bind to heme and thus interfere with heme catabolism in the parasite, were assayed for inhibitory activity in Plasmodium falciparum cultures and the results were compared to those obtained with Chinese hamster ovary (CHO) cells. The majority of the compounds displayed a similar ratio of inhibitory activity in the two culture systems; however, a number of the compounds tested showed promising anti-Plasmodium activity. The mechanism of action of these compounds remains unclear, however their inability to act synergistically with chloroquine suggests that, if they are inhibiting heme detoxification, they do so in a manner that does not complement the action of chloroquine. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.122
• 作为产物：
  描述：

  1,2-环氧丁烷 、 咪唑 、 乙酸乙酯 在 sodium hydride 、 盐酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以4%的产率得到1-acetoxy-2-(1H-imidazol-1-yl)butane
  参考文献：
  名称：

  Anti-Plasmodium activity of imidazole–dioxolane compounds

  摘要：

  A series of imidazole-dioxolane compounds, which we hypothesize should bind to heme and thus interfere with heme catabolism in the parasite, were assayed for inhibitory activity in Plasmodium falciparum cultures and the results were compared to those obtained with Chinese hamster ovary (CHO) cells. The majority of the compounds displayed a similar ratio of inhibitory activity in the two culture systems; however, a number of the compounds tested showed promising anti-Plasmodium activity. The mechanism of action of these compounds remains unclear, however their inability to act synergistically with chloroquine suggests that, if they are inhibiting heme detoxification, they do so in a manner that does not complement the action of chloroquine. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.122

文献信息

• Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System
  申请人：Gupta Ajay

  公开号：US20110319459A1

  公开（公告）日：2011-12-29

  Disclosed are compounds of the general formula (I): TC n D  (I), compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

  本发明涉及一般式（I）的化合物：TCnD（I），包括单独使用或与其他化疗药物联合使用的有效量的该化合物的组合物，以及用于治疗或预防癌症和抑制肿瘤组织生长的有用方法。这些化合物减弱了与增加血红素氧合酶活性相关的氧化损伤，并可以减少转化细胞中的细胞增殖。此外，所述化合物和组合物可用作神经保护剂，并用于治疗或预防中枢神经系统的神经退行性疾病和其他疾病。
• US7943650B2
  申请人：——

  公开号：US7943650B2

  公开（公告）日：2011-05-17
• US8513294B2
  申请人：——

  公开号：US8513294B2

  公开（公告）日：2013-08-20
• [EN] HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM<br/>[FR] INHIBITEURS DE L'HÈME-OXYGÉNASE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER ET DE MALADIES DU SYSTÈME NERVEUX CENTRAL
  申请人：OSTA BIOTECHNOLOGIES

  公开号：WO2008151437A1

  公开（公告）日：2008-12-18

  [EN] Disclosed are compounds of the general formula (1): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.
  [FR] L'invention porte sur des composés représentés par la formule générale (1), sur des compositions comprenant une quantité efficace desdits composés soit individuellement soit en combinaison avec d'autres agents chimiothérapeutiques, et sur des procédés utiles pour traiter ou prévenir le cancer et pour inhiber une croissance de tissu tumoral. Ces composés atténuent le dommage oxydant associé à une activité accrue de l'hème-oxygénase et permettent de réduire une prolifération cellulaire dans les cellules transformées. De plus, les composés et compositions décrits sont utiles en tant que neuroprotecteurs ainsi que pour traiter ou prévenir des troubles neurodégénératifs et autres maladies du système nerveux central.
• Anti-Plasmodium activity of imidazole–dioxolane compounds
  作者：Jason Z. Vlahakis、Robert T. Kinobe、Kanji Nakatsu、Walter A. Szarek、Ian E. Crandall

  DOI：10.1016/j.bmcl.2006.01.122

  日期：2006.5

  A series of imidazole-dioxolane compounds, which we hypothesize should bind to heme and thus interfere with heme catabolism in the parasite, were assayed for inhibitory activity in Plasmodium falciparum cultures and the results were compared to those obtained with Chinese hamster ovary (CHO) cells. The majority of the compounds displayed a similar ratio of inhibitory activity in the two culture systems; however, a number of the compounds tested showed promising anti-Plasmodium activity. The mechanism of action of these compounds remains unclear, however their inability to act synergistically with chloroquine suggests that, if they are inhibiting heme detoxification, they do so in a manner that does not complement the action of chloroquine. (C) 2006 Elsevier Ltd. All rights reserved.